Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 25 symbols : Nvs save search
Worldwide Malaria Diagnostics Industry to 2026 - Featuring Access Bio, Novartis and Olympus Among Others
Published: 2022-03-25 (Crawled : 21:00) - prnewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NINOF | $10.2 100
|
Consumer Durables
| Email alert
Add to watchlist
TMO | News | $544.01 0.46% 470K
|
Health Technology
| Email alert
Add to watchlist
DHR | $235.0 -0.58% 1.1M
|
Health Technology
| Email alert
Add to watchlist
NINOY | $9.56 1.3K
|
Manufacturing
| Email alert
Add to watchlist
ABT | News | $106.76 1.42% 3.8M
|
Health Technology
| Email alert
Add to watchlist
novartis diagnostics diagnostic malaria
Drugs for Immunotherapy Global Market Report 2022
Published: 2022-03-25 (Crawled : 18:00) - prnewswire.com
AZNCF | $138.24 800
|
Health Technology
|
| O: -6.55%
H: 7.81%
C: 7.56%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.28%
H: 1.09%
C: 0.18%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -1.58%
H: 1.16%
C: 0.23%
immunotherapy report market drug
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Cellular Immunotherapy Global Market Report 2022
Published: 2022-03-25 (Crawled : 14:00) - prnewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
immunotherapy report market
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
jakavi novartis disease positive chmp
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.